About: Enfuvirtide

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Enfuvirtide Goto Sponge Distinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	36 residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. N-terminal acetylated, C-terminal amide. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B45F5-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B45F6-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Greenberg ML, Cammack N: Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004 Aug;54(2):333-40. Epub 2004 Jul 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15231762 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	3.8 +/- 0.6 hrs (en)
http://linked.open...ugbank/indication	Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. (en)
http://linked.open...bank/manufacturer	Glaxosmithkline
sameAs	Enfuvirtide
Title	Enfuvirtide (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00109/identifier/bindingdb/50271301 http://linked.opendata.cz/resource/drugbank/drug/DB00109/identifier/drugbank/DB00109 http://linked.opendata.cz/resource/drugbank/drug/DB00109/identifier/genbank/U12055 http://linked.opendata.cz/resource/drugbank/drug/DB00109/identifier/national-drug-code-directory/0004-0380-39 http://linked.opendata.cz/resource/drugbank/drug/DB00109/identifier/uniprotkb/Q70626 http://linked.opendata.cz/resource/drugbank/drug/DB00109/identifier/pharmgkb/PA164744517 http://linked.opendata.cz/resource/drugbank/drug/DB00109/identifier/wikipedia/Enfuvirtide
http://linked.open...mechanismOfAction	Enfuvirtide binds to the first heptad-repeat (HR1) in the gp41 subunit of the viral envelope glycoprotein and prevents the conformational changes required for the fusion of viral and cellular membranes. It works by disrupting the HIV-1 molecular machinery at the final stage of fusion with the target cell, preventing uninfected cells from becoming infected. Enfuvirtide is a biomimetic peptide that was rationally designed to mimic components of the HIV-1 fusion machinery and displace them, preventing normal fusion. (en)
http://linked.open...drugbank/packager	F Hoffmann La Roche Ltd. F Hoffmann-La Roche Ltd. Gilead Sciences Inc. Pharmacia Inc.
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/2224008 http://linked.opendata.cz/resource/drugbank/patent/5464933 http://linked.opendata.cz/resource/drugbank/patent/6475491
http://linked.open.../drugbank/synonym	Envelope polyprotein GP160 precursor [Contains: Exterior membrane glycoprotein,GP120, Transmembrane glycoprotein,GP41] (en)
http://linked.open...umeOfDistribution	* 5.5 ± 1.1 L (en)
http://linked.open.../drug/hasAHFSCode	http://linked.opendata.cz/resource/AHFS/08-18-08-04
http://linked.open...nk/proteinBinding	92% (en)
foaf:page	http://www.drugs.com/cdi/enfuvirtide.html http://www.rxlist.com/cgi/generic3/fuzeon.htm
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B45FA-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B45F9-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Enfuvirtide
http://linked.open...ugbank/absorption	After a 90 mg single subcutaneous injection of Enfuvirtide into the abdomen in 12 HIV-1 infected subjects, the mean peak concentration is 4.59+/-1.5 ug/ml and the median time to peak concentration was 8 hours (ranged from 3 to12 hours). (en)
http://linked.open.../affectedOrganism	Human Immunodeficiency Virus (en)
http://linked.open...casRegistryNumber	159519-65-0 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	* 24.8 +/- 4.1 mL/h/kg [HIV-1 infected adult and pediatric subjects following a 90-mg single SC dose of enfuvirtide] * 30.6 +/- 10.6 mL/h/kg [Following 90-mg twice daily dosing of FUZEON SC in combination with other antiretroviral agents in HIV-1 infected subjects] * 40 +/- 17 mL/h/kg [pediatric patients in the presence of concomitant medications including antiretroviral agents receiving the 2 mg/kg twice daily dose] (en)
http://linked.open...gbank/containedIn	Fuzeon convenience kit
http://linked.open...nk/Hydrophobicity	http://linked.opendata.cz/resource/drugbank/property/271B45F7-363D-11E5-9242-09173F13E4C5
http://linked.open...Isoelectric-Point	http://linked.opendata.cz/resource/drugbank/property/271B45F8-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 117 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software